PERTH, Australia – Sydney-based Minomic International Ltd.'s Micheck prostate cancer diagnostic was more than twice as specific in screening for prostate cancer than the standard of care prostate specific antigen (PSA) screening technology, a recent clinical trial showed. The Micheck diagnostic met both primary endpoints in a U.S. multicenter trial in 384 patients. The trial was a prospective, non-randomized case-control study, with a primary endpoint of detecting prostate cancer versus no cancer, and a secondary endpoint of differentiating between aggressive and non-aggressive cancer. Read More
